Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting

Exclusive Partnership for AXIM Biotechnologies, Inc.

SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has started sales of its innovative point-of-care diagnostic tests for ocular surface disease at the American Academy of Ophthalmology Annual Meeting. Through an exclusive partnership, AXIM Biotechnologies is making their cutting-edge diagnostic test platform available to ophthalmologists and eye care professionals.

Revolutionizing Ocular Surface Disease Diagnosis

The launch of AXIM Biotechnologies’ point-of-care diagnostic test platform marks a significant milestone in the field of ophthalmology. This innovative technology allows for quick and accurate diagnosis of ocular surface diseases, providing healthcare professionals with valuable insights to guide treatment and improve patient outcomes. By offering these diagnostic tests through an exclusive partnership at a premier industry event like the American Academy of Ophthalmology Annual Meeting, AXIM Biotechnologies is poised to make a major impact in the field.

Impact on Individuals

For individual patients suffering from ocular surface diseases, the availability of AXIM Biotechnologies’ point-of-care diagnostic tests means faster and more accurate diagnosis, leading to quicker treatment and better management of their condition. This can result in improved quality of life and overall visual health for those affected by these challenging diseases.

Global Implications

On a larger scale, the introduction of AXIM Biotechnologies’ point-of-care diagnostic test platform has the potential to revolutionize the diagnosis and treatment of ocular surface diseases worldwide. By making advanced diagnostic technology more accessible to healthcare professionals, AXIM Biotechnologies is driving innovation and excellence in eye care on a global level. This could lead to improved outcomes for patients around the world and contribute to advancements in the field of ophthalmology.

Conclusion

The commencement of sales for AXIM Biotechnologies’ point-of-care diagnostic tests at the American Academy of Ophthalmology Annual Meeting represents a significant advancement in the diagnosis and treatment of ocular surface diseases. This exclusive partnership underscores the company’s commitment to innovation and excellence in eye care, with far-reaching implications for both individuals and the global healthcare community. By leveraging cutting-edge technology to improve diagnostic accuracy and patient outcomes, AXIM Biotechnologies is shaping the future of ophthalmology.